Tuning Transcription Factor Availability through Acetylation-Mediated Genomic Redistribution.


Journal

Molecular cell
ISSN: 1097-4164
Titre abrégé: Mol Cell
Pays: United States
ID NLM: 9802571

Informations de publication

Date de publication:
06 08 2020
Historique:
received: 02 10 2019
revised: 01 04 2020
accepted: 19 05 2020
pubmed: 13 6 2020
medline: 26 8 2020
entrez: 13 6 2020
Statut: ppublish

Résumé

It is widely assumed that decreasing transcription factor DNA-binding affinity reduces transcription initiation by diminishing occupancy of sequence-specific regulatory elements. However, in vivo transcription factors find their binding sites while confronted with a large excess of low-affinity degenerate motifs. Here, using the melanoma lineage survival oncogene MITF as a model, we show that low-affinity binding sites act as a competitive reservoir in vivo from which transcription factors are released by mitogen-activated protein kinase (MAPK)-stimulated acetylation to promote increased occupancy of their regulatory elements. Consequently, a low-DNA-binding-affinity acetylation-mimetic MITF mutation supports melanocyte development and drives tumorigenesis, whereas a high-affinity non-acetylatable mutant does not. The results reveal a paradoxical acetylation-mediated molecular clutch that tunes transcription factor availability via genome-wide redistribution and couples BRAF to tumorigenesis. Our results further suggest that p300/CREB-binding protein-mediated transcription factor acetylation may represent a common mechanism to control transcription factor availability.

Identifiants

pubmed: 32531202
pii: S1097-2765(20)30345-2
doi: 10.1016/j.molcel.2020.05.025
pmc: PMC7427332
pii:
doi:

Substances chimiques

MITF protein, human 0
Microphthalmia-Associated Transcription Factor 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

472-487.e10

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00007/9
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N010051/1
Pays : United Kingdom

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Interests The authors declare no competing interests.

Références

Oncotarget. 2015 Mar 10;6(7):5118-33
pubmed: 25742786
Bioinformatics. 2004 Nov 22;20(17):3246-8
pubmed: 15180930
Genome Res. 2014 May;24(5):751-60
pubmed: 24443471
J Biol Chem. 2004 Mar 12;279(11):9796-802
pubmed: 14701848
Cell. 1984 Dec;39(3 Pt 2):499-509
pubmed: 6096007
Mol Cell Biol. 2008 Jan;28(1):227-36
pubmed: 17938198
Nat Cell Biol. 2013 Aug;15(8):905-15
pubmed: 23851488
J Cell Biol. 2002 Sep 16;158(6):1079-87
pubmed: 12235125
Pigment Cell Melanoma Res. 2010 Feb;23(1):27-40
pubmed: 19995375
Oncogene. 2011 May 19;30(20):2319-32
pubmed: 21258399
Immunity. 2018 Jun 19;48(6):1119-1134.e7
pubmed: 29924977
Nature. 2012 Apr 11;484(7393):251-5
pubmed: 22498630
Bioinformatics. 2011 Jun 15;27(12):1696-7
pubmed: 21486936
Nat Methods. 2008 Feb;5(2):159-61
pubmed: 18176568
Proc Natl Acad Sci U S A. 2004 Jul 6;101(27):10042-7
pubmed: 15220471
Dev Cell. 2011 Oct 18;21(4):611-26
pubmed: 22014521
Biophys J. 2004 Jun;86(6):3473-95
pubmed: 15189848
Biophys J. 2009 Jul 8;97(1):337-46
pubmed: 19580772
Nat Biotechnol. 2008 Nov;26(11):1293-300
pubmed: 18978777
J Biol Chem. 2010 Oct 29;285(44):33959-70
pubmed: 20817729
Nat Rev Genet. 2009 Jul;10(7):443-56
pubmed: 19506578
Nature. 1998 Dec 10;396(6711):594-8
pubmed: 9859997
Mol Cell Biol. 2003 Apr;23(7):2587-99
pubmed: 12640139
Proc Natl Acad Sci U S A. 2018 Sep 11;115(37):E8668-E8677
pubmed: 30150413
Oncogene. 1997 Jun 26;14(25):3083-92
pubmed: 9223672
Nucleic Acids Res. 2011 Mar;39(6):e35
pubmed: 21177645
Nat Commun. 2017 Aug 22;8(1):313
pubmed: 28827596
Cell. 2014 Mar 13;156(6):1274-1285
pubmed: 24630727
Cell. 1993 Jul 30;74(2):395-404
pubmed: 8343963
Nature. 2005 Feb 17;433(7027):764-9
pubmed: 15716956
Cancer Discov. 2014 Jul;4(7):816-27
pubmed: 24771846
Nat Commun. 2014 Jul 18;5:4456
pubmed: 25034201
Nat Methods. 2013 May;10(5):421-6
pubmed: 23524394
Genes Dev. 2012 Dec 1;26(23):2647-58
pubmed: 23207919
Nat Methods. 2015 Mar;12(3):244-50, 3 p following 250
pubmed: 25599551
J Natl Cancer Inst. 1977 Jul;59(1):221-6
pubmed: 327080
J Biol Chem. 1998 Dec 4;273(49):33042-7
pubmed: 9830058
J Cell Biol. 2018 Apr 2;217(4):1181-1191
pubmed: 29378780
Oncogene. 1993 Aug;8(8):2221-9
pubmed: 7687762
Genes Dev. 2000 Jul 15;14(14):1712-28
pubmed: 10898786
Mol Cell Biol. 2006 Dec;26(23):8914-27
pubmed: 17000761
Methods Mol Biol. 2013;1042:117-37
pubmed: 23980004
Cancer Res. 2008 Oct 1;68(19):7788-94
pubmed: 18829533
Science. 2007 May 25;316(5828):1191-4
pubmed: 17525339
EMBO Rep. 2020 Jan 7;21(1):e48335
pubmed: 31750630
Oncogene. 2011 Jul 7;30(27):3036-48
pubmed: 21358674
Pigment Cell Melanoma Res. 2019 Jul;32(4):500-509
pubmed: 30548162
J Natl Cancer Inst. 1973 Nov;51(5):1417-23
pubmed: 4357758
Pigment Cell Melanoma Res. 2019 Nov;32(6):792-808
pubmed: 31207090
J Clin Invest. 2010 Dec;120(12):4316-31
pubmed: 21084751
Elife. 2014 Jun 12;3:
pubmed: 24925319
J Biol Chem. 2007 Jan 12;282(2):956-67
pubmed: 17110376
Nat Commun. 2014 Dec 15;5:5712
pubmed: 25502142
J Biol Chem. 2007 Sep 14;282(37):27215-28
pubmed: 17623675
J Cell Sci. 2015 Aug 1;128(15):2938-50
pubmed: 26092939
Nucleic Acids Res. 2012 Aug;40(15):e119
pubmed: 22844090
Nucleic Acids Res. 1993 Nov 25;21(23):5372-6
pubmed: 8265351
Mol Endocrinol. 2005 Sep;19(9):2283-98
pubmed: 15890677
Genes Dev. 2006 Dec 15;20(24):3426-39
pubmed: 17182868
Nat Methods. 2012 Mar 04;9(4):357-9
pubmed: 22388286
Pigment Cell Melanoma Res. 2019 Jan;32(1):41-54
pubmed: 29938923
Genome Biol. 2008;9(9):R137
pubmed: 18798982
Cancer Res. 2010 May 1;70(9):3813-22
pubmed: 20388797
Mol Cell. 2010 May 28;38(4):576-89
pubmed: 20513432
Elife. 2015 Mar 24;4:
pubmed: 25803486
Sci Rep. 2016 Oct 06;6:34808
pubmed: 27708426
Cell. 2014 Mar 13;156(6):1312-1323
pubmed: 24612990
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Science. 1990 Nov 23;250(4984):1104-10
pubmed: 2174572
Development. 1999 Sep;126(17):3757-67
pubmed: 10433906
Sci Rep. 2019 Jan 31;9(1):1055
pubmed: 30705290
Pigment Cell Melanoma Res. 2008 Dec;21(6):665-76
pubmed: 19067971
Science. 2000 Feb 18;287(5456):1262-5
pubmed: 10678832
Biophys J. 2011 Dec 7;101(11):2592-600
pubmed: 22261046
Nat Commun. 2015 Apr 09;6:6683
pubmed: 25865119
Mol Cell. 2019 Sep 19;75(6):1161-1177.e11
pubmed: 31421980
Proc Natl Acad Sci U S A. 2015 Feb 3;112(5):E420-9
pubmed: 25605940
Nucleic Acids Res. 2014 Jul;42(Web Server issue):W187-91
pubmed: 24799436
Cell. 1997 Aug 22;90(4):595-606
pubmed: 9288740
Chromosome Res. 2011 Jan;19(1):83-98
pubmed: 21181254
Cell. 2007 Mar 9;128(5):853-64
pubmed: 17350573
Nature. 2005 Jul 7;436(7047):117-22
pubmed: 16001072
Nat Cell Biol. 2001 Jan;3(1):15-23
pubmed: 11146621
J Biol Chem. 2006 Apr 14;281(15):10365-73
pubmed: 16455654
Cell. 2002 Jun 14;109(6):707-18
pubmed: 12086670
Proc Natl Acad Sci U S A. 2012 Dec 26;109(52):21330-5
pubmed: 23236164
Nature. 2011 Oct 19;480(7375):94-8
pubmed: 22012259
Sci Rep. 2015 Jun 03;5:10662
pubmed: 26039515
Genes Dev. 2019 Aug 1;33(15-16):983-1007
pubmed: 31123060
EMBO J. 1992 Nov;11(11):4103-9
pubmed: 1327757
Mol Cell. 2018 Nov 1;72(3):444-456.e7
pubmed: 30401431
Mol Cell Biol. 1992 Aug;12(8):3653-62
pubmed: 1321344
Pigment Cell Melanoma Res. 2010 Dec;23(6):746-59
pubmed: 20726948
Proc Natl Acad Sci U S A. 1974 Dec;71(12):4808-12
pubmed: 4612528
Oncogene. 2011 May 19;30(20):2307-18
pubmed: 21278797
EMBO J. 1993 Dec 15;12(13):5075-82
pubmed: 8262050
Blood. 1996 Aug 15;88(4):1225-33
pubmed: 8695840
Bioinformatics. 2010 Mar 15;26(6):841-2
pubmed: 20110278
Mol Cell Biol. 1998 Dec;18(12):6930-8
pubmed: 9819381
Biochem J. 2009 Mar 1;418(2):463-73
pubmed: 18834332
Elife. 2018 Jan 04;7:
pubmed: 29300163
Elife. 2016 Nov 19;5:
pubmed: 27855781

Auteurs

Pakavarin Louphrasitthiphol (P)

Ludwig Institute for Cancer Research, Nuffield Department of Clinical Medicine, University of Oxford, Headington, Oxford OX3 7DQ, UK; Department of Gastrointestinal and Hepato-Biliary-Pancreatic Surgery, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, Japan.

Robert Siddaway (R)

Ludwig Institute for Cancer Research, Nuffield Department of Clinical Medicine, University of Oxford, Headington, Oxford OX3 7DQ, UK.

Alessia Loffreda (A)

Experimental Imaging Center, Cancer Imaging Unit, IRCCS San Raffaele Scientific Institute, Via Olgettina 58, 20132 Milan, Italy; Fondazione CEN, European Center for Nanomedicine, 20133 Milan, Italy.

Vivian Pogenberg (V)

European Molecular Biology Laboratory, Hamburg Unit, Notkestrasse 25a, 22607 Hamburg, Germany & University Hamburg Medical Centre Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany.

Hans Friedrichsen (H)

Ludwig Institute for Cancer Research, Nuffield Department of Clinical Medicine, University of Oxford, Headington, Oxford OX3 7DQ, UK.

Alexander Schepsky (A)

Ludwig Institute for Cancer Research, Nuffield Department of Clinical Medicine, University of Oxford, Headington, Oxford OX3 7DQ, UK; Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Iceland, Sturlugata 8, 101 Reykjavik, Iceland.

Zhiqiang Zeng (Z)

MRC Institute of Genetics and Molecular Medicine, MRC Human Genetics Unit and Edinburgh Cancer Research UK Centre, Crewe Road South, Edinburgh EH4 2XR, UK.

Min Lu (M)

Ludwig Institute for Cancer Research, Nuffield Department of Clinical Medicine, University of Oxford, Headington, Oxford OX3 7DQ, UK.

Thomas Strub (T)

Institut de Génetique et Biologie Moléculaire et Cellulaire (IGBMC), Equipe labéllisée Ligue contre le Cancer, 1 rue Laurent Fries, 67404 Illkirch Cedex, France.

Rasmus Freter (R)

Ludwig Institute for Cancer Research, Nuffield Department of Clinical Medicine, University of Oxford, Headington, Oxford OX3 7DQ, UK.

Richard Lisle (R)

Ludwig Institute for Cancer Research, Nuffield Department of Clinical Medicine, University of Oxford, Headington, Oxford OX3 7DQ, UK.

Eda Suer (E)

Ludwig Institute for Cancer Research, Nuffield Department of Clinical Medicine, University of Oxford, Headington, Oxford OX3 7DQ, UK.

Benjamin Thomas (B)

Central Proteomics Facility, Sir William Dunn Pathology School, Oxford University, Oxford OX1 3RE, UK.

Benjamin Schuster-Böckler (B)

Ludwig Institute for Cancer Research, Big Data Institute, University of Oxford, Headington, Oxford OX3 7LF, UK.

Panagis Filippakopoulos (P)

Structural Genomics Consortium, Nuffield Department of Clinical Medicine, University of Oxford, Headington, Oxford OX3 7DQ, UK.

Mark Middleton (M)

Oxford NIHR Biomedical Research Centre, Department of Oncology, Churchill Hospital, Oxford OX3 7LE, UK.

Xin Lu (X)

Ludwig Institute for Cancer Research, Nuffield Department of Clinical Medicine, University of Oxford, Headington, Oxford OX3 7DQ, UK.

E Elizabeth Patton (EE)

MRC Institute of Genetics and Molecular Medicine, MRC Human Genetics Unit and Edinburgh Cancer Research UK Centre, Crewe Road South, Edinburgh EH4 2XR, UK.

Irwin Davidson (I)

Institut de Génetique et Biologie Moléculaire et Cellulaire (IGBMC), Equipe labéllisée Ligue contre le Cancer, 1 rue Laurent Fries, 67404 Illkirch Cedex, France.

Jean-Philippe Lambert (JP)

Department of Molecular Medicine and Cancer Research Centre, Université Laval, Quebec, QC, Canada; CHU de Québec Research Center, CHUL, 2705 Boulevard Laurier, Quebec G1V 4G2, QC, Canada.

Matthias Wilmanns (M)

European Molecular Biology Laboratory, Hamburg Unit, Notkestrasse 25a, 22607 Hamburg, Germany & University Hamburg Medical Centre Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany.

Eiríkur Steingrímsson (E)

Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Iceland, Sturlugata 8, 101 Reykjavik, Iceland.

Davide Mazza (D)

Experimental Imaging Center, Cancer Imaging Unit, IRCCS San Raffaele Scientific Institute, Via Olgettina 58, 20132 Milan, Italy; Fondazione CEN, European Center for Nanomedicine, 20133 Milan, Italy. Electronic address: mazza.davide@hsr.it.

Colin R Goding (CR)

Ludwig Institute for Cancer Research, Nuffield Department of Clinical Medicine, University of Oxford, Headington, Oxford OX3 7DQ, UK. Electronic address: colin.goding@ludwig.ox.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH